-
AI for Pricing Reimbursement: When to Green-Light, When to Red-Light?
Sep 9, 2025, 16:22 PM -
The Impact of Menopausal Hormone Therapy on Productivity and Health Care Utilization in Women: A Finnish Claims Database Study
Sep 9, 2025, 16:22 PM -
A Systematic Literature Review of Prognostic Factors in Advanced Merkel Cell Carcinoma
Sep 9, 2025, 16:22 PM -
Real-World Evidence of Atezolizumab in Unresectable Recurrent NSCLC: Insights From Japan's Next-Generation Medical Infrastructure Act
Sep 9, 2025, 16:22 PM -
Addressing Bias in Indirect Treatment Comparisons: A Framework for Identifying TEMs and PVs
Sep 9, 2025, 16:22 PM -
Does the Abortion Pill Harm Women? Serious Adverse Events Following Mifepristone Abortion in US Commercial and Medicaid Populations
Sep 9, 2025, 16:22 PM -
Generative A-Powered Extraction of Immune-Related Adverse Events From Oncology Case Reports
Sep 9, 2025, 16:22 PM -
An Adjusted Indirect Comparison of Once-Weekly Insulin Efsitora Alfa vs. Insulin Icodec for Adults With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Sep 9, 2025, 16:22 PM -
AI for Rapid Data Extraction: A Case Study on the Economic and Caregiver Burden of Motor Neuron Disease
Sep 9, 2025, 16:22 PM -
Humanistic and Financial Burden Experienced by Nonprofessional Care Partners of Patients With Mild Cognitive Impairment and Dementia Due to Alzheimer’s Disease: Results From a Real-World Survey in Spain
Sep 9, 2025, 16:22 PM -
Global Trade Shocks and Exchange Rate Effects on Pharmaceutical Reference Pricing: Implications of EU Stimulus for US MFN Policy
Sep 9, 2025, 16:22 PM -
Maximizing Profits Through Pricing: Opportunities in Portugal's Pharma Sector
Sep 9, 2025, 16:22 PM -
Missing Health State Utility Values (HSUV) in NICE Oncology Appraisals: A Systematic Review of Utility Data Reporting and Handling Practices
Sep 9, 2025, 16:22 PM -
Scientific Outcome of ISPOR Conferences: An Analysis of 67,055 Abstracts Presented at 54 ISPOR Conferences Between 2002-2024
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Aztreonam Avibactam (ATMAVI) ± Metronidazole (MTZ) for the Treatment of Complicated Intra-Abdominal Infections (cIAIs) and Ventilator-Associated Hospital-Acquired Pneumonia (HAP/VAP) Caused by Suspected MBL-Producing...
Sep 9, 2025, 16:22 PM -
The Health Impact of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab Treatment for High-Risk Early Stage Triple-Negative Breast Cancer (eTNBC) in Türkiye
Sep 9, 2025, 16:22 PM -
Influence of NICE Real-World Evidence Framework on HTA Submissions: Sensitivity Analyses in Real-World External Control Arm Studies
Sep 9, 2025, 16:22 PM -
Matching-Adjusted Indirect Comparison Between Garadacimab and Donidalorsen for Long-Term Prophylaxis in Hereditary Angioedema
Sep 9, 2025, 16:22 PM -
Comparison of the Early Access and Postmarket Evaluation Systems in South Korea and Germany’s DIGA
Sep 9, 2025, 16:22 PM -
Early Economic Modeling of Mutant TNF (mutTNF) As a BBB-Permeabilizing Adjunct in Breast Cancer Brain Metastases: A UK NHS Perspective
Sep 9, 2025, 16:22 PM
